{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:19:27Z","timestamp":1784611167727,"version":"3.55.0"},"reference-count":13,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pusan National University Yangsan Hospital"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Pneumocystis jirovecii pneumonia (PJP) is a rare opportunistic infection in patients with solid malignancies. This study aimed to examine the characteristics of patients with solid cancers and PJP. We retrospectively reviewed the medical records of patients with solid tumors and PJP over an 11-year period, enrolling a total of 47 patients (30-day survival group: n = 20, 30-day mortality group: n = 27). Only 34% of patients received \u226520 mg of prednisolone for \u22652 weeks, and the 30-day mortality rate was 57.4%. The 30-day survival group included more women and patients with colon cancer than the mortality group. Furthermore, absolute lymphocyte counts (ALCs) were decreased at PJP symptom onset, as compared with the values observed 1\u20133 months earlier. Increased oxygen demand and low ALCs after 5\u20137 days of PJP treatment were also related to poor prognosis. Due to the limitations of this retrospective study, further studies that adhere to the PJP criteria of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium will be needed to evaluate PJP in solid malignancies more clearly.<\/jats:p>","DOI":"10.3390\/pathogens11101169","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T02:10:27Z","timestamp":1665540627000},"page":"1169","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pneumocystis jirovecii Pneumonia in Patients with Solid Malignancies: A Retrospective Study in Two Hospitals"],"prefix":"10.3390","volume":"11","author":[{"given":"Cheon-Hoo","family":"Jeon","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158, Paryong-ro, Masanhoewon-gu, Changwon 51353, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7763-8940","authenticated-orcid":false,"given":"Si-Ho","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158, Paryong-ro, Masanhoewon-gu, Changwon 51353, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1603-0963","authenticated-orcid":false,"given":"Seulki","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Internal Medicine, Pusan National University Yangsan Hospital, 20, Geumo-ro, Mulgeum-eup, Yangsan 50612, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moonsuk","family":"Bae","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Internal Medicine, Pusan National University Yangsan Hospital, 20, Geumo-ro, Mulgeum-eup, Yangsan 50612, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Jin","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Internal Medicine, Pusan National University Yangsan Hospital, 20, Geumo-ro, Mulgeum-eup, Yangsan 50612, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7939-9744","authenticated-orcid":false,"given":"Seungjin","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Internal Medicine, Pusan National University Yangsan Hospital, 20, Geumo-ro, Mulgeum-eup, Yangsan 50612, Korea"},{"name":"Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, 20, Geumo-ro, Mulgeum-eup, Yangsan 50612, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/s41598-019-38618-3","article-title":"Risk factors and clinical characteristics of Pneumocystis jirovecii pneumonia in lung cancer","volume":"9","author":"Lee","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Takeuchi, K., and Yakushijin, Y. (2021). Pneumocystis jirovecii pneumonia prophylaxis for cancer patients during chemotherapy. Pathogens, 10.","DOI":"10.3390\/pathogens10020237"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Takeda, K., Harada, S., Hayama, B., Hoashi, K., Enokida, T., Sasaki, T., Okamoto, K., Nakano, K., and Ohkushi, D. (2021). Clinical characteristics and risk factors associated with Pneumocystis jirovecii infection in patients with solid tumors: Study of thirteen-year medical records of a large cancer center. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08727-2"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/jama.1992.03480060078034","article-title":"Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital","volume":"267","author":"Sepkowitz","year":"1992","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ricciardi, A., Gentilotti, E., Coppola, L., Maffongelli, G., Cerva, C., Malagnino, V., Mari, A., Di Veroli, A., Berrilli, F., and Apice, F. (2017). Infectious disease ward admission positively influences P. jiroveci pneumonia (PjP) outcome: A retrospective analysis of 116 HIV-positive and HIV-negative immunocompromised patients. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0176881"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/17843286.2017.1305136","article-title":"Pneumocystis jiroveci pneumonia (PJP) in non-HIV immunocompromised individuals","volume":"72","author":"Schoovaerts","year":"2017","journal-title":"Acta Clin. Belg."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Assal, M., Lambert, J., Chow-Chine, L., Bisbal, M., Servan, L., Gonzalez, F., de Guibert, J.M., Faucher, M., Vey, N., and Sannini, A. (2021). Prognostic impact of early adjunctive corticosteroid therapy in non-HIV oncology or haematology patients with Pneumocystis jirovecii pneumonia: A propensity score analysis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0250611"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Gr\u00f8nseth, S., Rogne, T., Hannula, R., \u00c5svold, B.O., Afset, J.E., and Dam\u00e5s, J.K. (2021). Epidemiological and clinical characteristics of immunocompromised patients infected with Pneumocystis jirovecii in a twelve-year retrospective study from Norway. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06144-1"},{"key":"ref_9","first-page":"e21812","article-title":"Pneumocystis jirovecii pneumonia in three patients with breast cancer receiving neoadjuvant dose-dense chemotherapy","volume":"14","author":"Shiiba","year":"2022","journal-title":"Cureus"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/imj.12599","article-title":"Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014","volume":"44","author":"Cooley","year":"2014","journal-title":"Intern. Med. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1378\/chest.118.3.712","article-title":"Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection","volume":"118","author":"Mansharamani","year":"2000","journal-title":"Chest"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"680108","DOI":"10.3389\/fpubh.2021.680108","article-title":"Risk factors of mortality from Pneumocystis pneumonia in non-HIV patients: A meta-analysis","volume":"9","author":"Wang","year":"2021","journal-title":"Front. Public Health"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/11\/10\/1169\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:49:50Z","timestamp":1760143790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/11\/10\/1169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":13,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["pathogens11101169"],"URL":"https:\/\/doi.org\/10.3390\/pathogens11101169","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]}}}